Followers | 129 |
Posts | 2150 |
Boards Moderated | 1 |
Alias Born | 12/27/2007 |
Wednesday, April 09, 2014 8:20:33 AM
Sodium Thiosulfate (STS) Phase 3 Clinical Study Update ..READ
Looks like we hit the Jackpot here ...Maybe this is the reason for the heavy buying by Insiders ! This Low float sleeping giant will explode if final results is also positive .GL
-------
Adherex Announces Sodium Thiosulfate Clinical Study Update
~ Data have been submitted to ASCO 2014~
Adherex’s collaborator the Children’s Oncology Group (COG) posted top-line results from a Phase III trial of Adherex’s lead candidate STS to clinicaltrials.gov last week. The data are incomplete and no statistical analysis was performed. A full analysis of secondary endpoints such as event free survival and overall survival was not posted. Any interpretation should be limited until Adherex reports the full data, which is expected at the American Society of Clinical Oncology (ASCO) meeting in June 2014.
Posted Data, though Incomplete, is Encouraging. According to the posted results, the data regarding the frequency of patients with hearing loss is encouraging, and may support the primary endpoint after a full statistical analysis. The primary endpoint of the trial is hearing protection in pediatric oncology patients undergoing platinum-based chemotherapy.
The posted data show that out of 56 patients in the cisplatin arm of the study, 31 (55%) experienced hearing loss. For the 49 patients treated with STS and cisplatin, 14 (29%) experienced hearing loss. Information posted on the website is incomplete and final results may differ from those presented.
Adherex has announced that COG has already submitted an abstract for presentation at 2014 American Society of Clinical Oncology Meeting. The Company indicated that no other study data is available for public disclosure at this time.
Recent FENC News
- Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024 • GlobeNewswire Inc. • 05/07/2024 10:15:00 PM
- Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/21/2024 10:00:00 AM
- Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024 • GlobeNewswire Inc. • 03/19/2024 10:01:00 AM
- Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand • PR Newswire (US) • 03/18/2024 07:00:00 AM
- Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand • GlobeNewswire Inc. • 03/18/2024 01:00:00 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/06/2024 09:07:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:04:59 PM
- Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results • GlobeNewswire Inc. • 02/29/2024 12:04:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 03:47:17 PM
- FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin • GlobeNewswire Inc. • 02/01/2024 10:55:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 10:24:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/05/2024 09:45:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/04/2024 09:42:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 09:30:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/28/2023 08:51:07 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/18/2023 05:15:11 AM
- Fennec Announces Incremental $5 Million Investment from Petrichor • GlobeNewswire Inc. • 12/05/2023 10:55:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/16/2023 09:05:27 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/09/2023 09:56:56 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:52:31 PM
- Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 11/09/2023 09:50:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/09/2023 09:38:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/08/2023 11:19:45 PM
- Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/06/2023 10:59:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/03/2023 09:19:04 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM